BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/28/2014 5:50:00 PM | Browse: 536 | Download: 276
Publication Name World Journal of Gastroenterology
Manuscript ID 5495
Country of Manuscript Source Denmark
2013-09-11 09:11
Peer-Review Started
2013-09-13 11:27
To Make the First Decision
2013-10-29 12:29
Return for Revision
2013-11-04 19:14
2013-11-18 00:37
Second Decision
2014-01-02 10:54
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-01-02 12:01
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
2014-01-12 23:49
Typeset the Manuscript
2014-02-20 18:29
Publish the Manuscript Online
2014-04-29 09:53
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Specialty Oncology
Manuscript Type Topic Highlights
Article Title Role of human epidermal growth factor receptor 2 in gastric cancer: Biological and pharmacological aspects
Manuscript Source Invited Manuscript
All Author List Jan Trøst Jørgensen
Funding Agency and Grant Number
Corresponding author Jan Trost Jorgensen, MSc Pharm, PhD, Dx-Rx Institute, Baunevaenget 76, 3480 Fredensborg, Denmark. jan.trost@dx-rx.dk
Keywords Human epidermal growth factor receptor 2; Gastric cancer; Prognostic; Companion diagnostics; Trastuzumab; Pertuzumab; Ado-trastuzumab emtansine; Lapatinib
Core Tip Amplification of the human epidermal growth factor receptor 2 (HER2) gene and overexpression of the HER2 protein can be detected in 15%-20% of patients with gastric and gastroesophageal junction (GEJ) cancer. Recently, HER2 has proven to be an important target for treatment with trastuzumab in these patients, and a positive HER2 status seems to possess both prognostic and predictive properties. A number of new compounds directed towards HER2 and other members of the HER family is currently under development. This review will discuss the current status of HER2 in gastric and GEJ cancer and the future direction in relation to HER2 target therapy.
Publish Date 2014-04-29 09:53
Citation Jørgensen JT. Role of human epidermal growth factor receptor 2 in gastric cancer: Biological and pharmacological aspects. World J Gastroenterol 2014; 20(16): 4526-4535
Url http://www.wjgnet.com/1007-9327/full/v20/i16/4526.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i16.4526
Full Article (PDF) WJG-20-4526.pdf
Full Article (Word) WJG-20-4526.doc
Manuscript File 5495-Review.docx
Answering Reviewers 5495-Answering reviewers.pdf
Copyright License Agreement 5495-Copyright assignment.pdf
Peer-review Report 5495-Peer review(s).pdf
Scientific Editor Work List 5495-Scientific editor work list.doc